PMG Pharmascience Co., Ltd. (KOSDAQ:A073570) announced a private placement of Series 14 domestic bearer type non-guaranteed private placement convertible bonds and series 15 domestic bearer type interest part non-guaranteed private placement convertible bonds for gross proceeds of KRW 15,000,000,000 on June 17, 2021. The transaction will include participation from Eugene Investment & Securities Co.,Ltd. (KOSE:A001200) for KRW 5,000,000,000, JJ Assets Co., Ltd. for KRW 1,300,000,000, Mirae Asset Securities Co., Ltd. (KOSE:A006800) for KRW 1,000,000,000, JW Holdings Corporation (KOSE:A096760) for KRW 700,000,000, NH Absolute Return Professional Investment Private Equity Trust No. 1 for KRW 1,000,000,000, JC Asset KOSDAQ Venture Specialized Investment Criminal Equity Trust No.

6 for KRW 500,000,000 and JC Asset KOSDAQ Venture Specialized Investment Criminal Equity Investment Trust No.7 for KRW 500,000,000 for series 15 bonds and Kiwoom Securities Co., Ltd. (KOSE:A039490) for KRW 5,000,000,000 for series 14 bonds. The bonds are zero coupon bonds and will have a yield to maturity of 2%. The bonds will mature on June 21, 2024.

The bonds will be fully convertible into 9,063,444 shares at a fixed conversion price of KRW 1,655 per share between June 21, 2022 and May 21, 2024. The expected subscription and payment date for the bonds is June 21, 2021. The transaction has been approved by the board of directors of the company.